Verge Genomics and Ferrer partner to co-develop ALS drug VRG50635 in selected regions.

Verge Genomics and Ferrer, a rare neurological disorder-focused pharmaceutical company, have announced a strategic collaboration to co-develop VRG50635, a clinical-stage drug for treating sporadic and familial forms of amyotrophic lateral sclerosis (ALS). VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, discovered using CONVERGE®, Verge's AI-powered platform. Ferrer will acquire the rights for the drug in Europe, Central and South America, Southeast Asia, and Japan, while Verge retains the license for the US and other territories.

March 25, 2024
5 Articles